ClinicalTrials.gg
RecruitingNCT07317076Updated May 19, 2026

GT Metabolic Magnet System in Adults With Gastrointestinal Disorders

An interventional study of Magnet System in Gastric Outlet Obstruction, Small Bowel Obstruction and Superior Mesenteric Artery Syndrome, sponsored by GT Metabolic Solutions, Inc.. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by GT Metabolic Solutions, Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Evaluate the performance and safety of the GT Metabolic Magnet System for the creation of side-to-side compression anastomosis in the stomach and/or small bowel in conditions requiring an anastomosis as part of the underlying clinical treatment.

Read the detailed description

Evaluate the performance and safety of the Magnet System as a surgical tool for anastomosis in participants who have partial small bowel obstruction, SMAS, or GOO due to their similarities (they all involve a physical impediment (e.g., compression of the intestinal lumen) and/or mechanical blockage of the GI tract).

02

Conditions studied

  • Gastric Outlet Obstruction
  • Small Bowel Obstruction
  • Superior Mesenteric Artery Syndrome

Keywords

  • Magnet System
  • GT Metabolic Solutions, Inc.
03

In context

Gastric Outlet Obstruction

38 studies on the registry are indexed under Gastric Outlet Obstruction; 14 are open to participants now.

This study's planned enrollment of 35 is below the median of 69 across 28 interventional studies indexed under Gastric Outlet Obstruction.

Browse Gastric Outlet Obstruction studies →

Lead sponsor

GT Metabolic Solutions, Inc. is the lead sponsor of 14 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Indicated for gastrointestinal surgery requiring a gastric and/or small bowel anastomosis, without need for immediate lumen patency, and meets one of the following criteria:

    1. Superior mesenteric artery syndrome (SMAS); OR
    2. Gastric outlet obstruction (GOO); OR
    3. Partial small bowel obstruction.
  • Meets the surgical clearance requirements as governed by the investigator's institution.
  • If a child-bearing female, subject must commit to not becoming pregnant and agree to use for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Other gastrointestinal or abdominal surgeries planned concurrently or within the study follow-up period (e.g., bariatric surgery such as sleeve gastrectomy).
  • Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contraindicate the anastomosis or study procedure, including scarring and abnormal anatomy at the anastomosis sites.
  • Any anomaly precluding gastrointestinal access by gastroscope / endoscope, catheters, and associated manipulation techniques for device placement.
  • Any condition or disease that precludes laparoscopic surgery.
  • Implantable pacemaker, defibrillator, other active and/or metallic implant that may interfere with or be adversely impacted by a temporary magnetic implant (Magnet System) and associated procedures.
  • Unhealed ulcers, bleeding lesions, tumor, diseased tissue or any other lesion at or distal to the target Magnet deployment sites.
  • Any need for immediate lumen patency while the anastomosis is formed.
  • History of prior or current .
  • Expected need for Magnetic Resonance Imaging (MRI) within the first 3 months post-procedure (or before if Magnet expulsion is confirmed radiologically).
  • Known allergies to the device components (including the biofragmentable material PGLA or similar compounds) or contrast media.
  • Pregnant, lactating, or planning pregnancy during the clinical investigation and follow up period.
  • Currently participating in an drug, biologic, or medical device or other interventional clinical study.
  • Presence of other anatomic or comorbid conditions, or medical, social or psychological conditions that, in the investigator's opinion, could limit the participant's ability to participate in the clinical investigation or to comply with follow-up requirements.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Magnet System

    GT Metabolic Magnet System comprised of GT Metabolic Magnet System ("Magnet System")

    Device: Magnet System

Interventions

  • DeviceMagnet System

    Magnetic compression anastomoses for intestinal diversion in subjects with small bowel obstruction, gastric outlet obstruction, or superior mesenteric artery syndrome.

06

What researchers measure

Primary outcomes

  1. Magnet Placement

    Placement and connection of two intraluminal Magnet.

    Time frame: 1 day

  2. Natural Magnet Passage

    Successful passage of magnets without surgical reintervention

    Time frame: 90 days

  3. Anastomosis Patency

    Creation of a patent anastomosis confirmed radiologically.

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07317076
Lead sponsor
GT Metabolic Solutions, Inc.
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Dec 9, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
May 19, 2026

Study contacts

Lisa Griffin Vincent, PhD, MA
Contact
clinical@gtmetabolic.com
+1 763-200-1416
Josh Schumacher
Contact
clinical@gtmetabolic.com
+1 763-200-1416

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion